abrdn Life Sciences Investors (NYSE:HQL) Short Interest Update

Key Points

• Short interest fell 70.6% to 18,442 shares as of July 31, representing approximately 0.1% of HQL’s outstanding shares and just 0.1 days of average trading volume.
• Institutional ownership stands at 32.21%, with several firms increasing their positions, including First Trust Advisors, Royal Bank of Canada, NewEdge Advisors, and Raymond James Financial.
• HQL shares opened at $21.34, near their 52-week high of $21.32, while the fund announced a quarterly dividend of $0.62, equal to an annualized $2.48 payout and an 11.6% yield.

abrdn Life Sciences Investors (NYSE:HQL - Get Free Report) was the recipient of a large decrease in short interest in July. As of July 31st, there was short interest totaling 18,442 shares, a decrease of 70.6% from the July 15th total of 62,733 shares. Approximately 0.1% of the shares of the company are sold short. Based on an average daily volume of 177,512 shares, the short-interest ratio is currently 0.1 days.

Institutional Trading of abrdn Life Sciences Investors

Institutional investors and hedge funds have recently modified their holdings of the company. Royal Bank of Canada boosted its holdings in abrdn Life Sciences Investors by 53.3% in the 1st quarter. Royal Bank of Canada now owns 73,475 shares of the company's stock worth $934,000 after buying an additional 25,542 shares during the period. NewEdge Advisors LLC lifted its position in shares of abrdn Life Sciences Investors by 43.1% in the first quarter. NewEdge Advisors LLC now owns 32,500 shares of the company's stock valued at $412,000 after acquiring an additional 9,785 shares in the last quarter. First Trust Advisors LP lifted its holdings in abrdn Life Sciences Investors by 112.2% in the 2nd quarter. First Trust Advisors LP now owns 35,321 shares of the company's stock worth $452,000 after purchasing an additional 18,674 shares in the last quarter. Raymond James Financial Inc. lifted its holdings in abrdn Life Sciences Investors by 20.3% in the 2nd quarter. Raymond James Financial Inc. now owns 375,960 shares of the company's stock worth $4,816,000 after purchasing an additional 63,429 shares in the last quarter. Finally, Clough Capital Partners L P bought a new position in abrdn Life Sciences Investors in the 2nd quarter worth approximately $318,000. 32.21% of the stock is currently owned by institutional investors.

abrdn Life Sciences Investors Stock Performance

Shares of HQL opened at $21.34 on Thursday. The business has a 50-day simple moving average of $19.19 and a two-hundred day simple moving average of $17.84. abrdn Life Sciences Investors has a 52 week low of $13.44 and a 52 week high of $21.32.

abrdn Life Sciences Investors Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, September 30th. Investors of record on Monday, August 24th will be issued a $0.62 dividend. This represents a $2.48 annualized dividend and a yield of 11.6%. The ex-dividend date of this dividend is Monday, August 24th.

abrdn Life Sciences Investors Company Profile

abrdn Life Sciences Investors NYSE: HQL is a closed-end management investment company that seeks capital appreciation through investment in the life sciences sector. Established in 1994, the trust focuses on equity and equity-related securities of companies engaged in biotechnology, pharmaceuticals, medical devices, diagnostics and related fields. Its closed-end structure allows portfolio managers to maintain a stable pool of capital, pursue long-term investment strategies and employ leverage when deemed appropriate.

The fund’s portfolio spans both public and private companies, with an emphasis on businesses driving innovation in drug development, gene therapy, precision medicine and healthcare technology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source